Login
$EIKN
$5.39 -$0.60 (9.95%) Live

$EIKN 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Eikon Therapeutics Reports Third Quarter 2026 Financial Results

26 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

14 Aug 2026 8-K: Regulation FD Disclosure

Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking stat...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Eikon Therapeutics Reports Second Quarter 2026 Financial Results

03 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective July 31, 2026, Leon Chen, Ph.D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the “Company”). Dr. Chen’s and Mr. Wolfe’s resignations were not because of a disagreement with the Company on a...

10 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 5, 2026, the Board of Directors (the “Board”) of Eikon Therapeutics, Inc. (the “Company”) appointed Ma. Fatima D. Francisco to the Board as a Class I director, effective June 15, 2026. Ms. Francisco has been appointed to serve un...

01 Jun 2026 8-K: Regulation FD Disclosure; Other Events

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

11 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

30 Mar 2026 8-K: Results of Operations and Financial Condition

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

06 Feb 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Eikon Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”),

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support